First Patient Included in AlzeCure’s Phase II Clinical Trial in Neuropathic Pain with Non-opioid ACD440 – BioSpace

STOCKHOLM, SE / ACCESSWIRE / June 21, 2022 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical agency that develops a broad portfolio of drug candidates for illnesss have an effect oning the central nervous system, with tasks in each Alzheimer’s illness and ache, right now introduced that The primary affected person has been included in a Half II medical trial with ACD440, the main non-opioid drug candidate Inside the Painless platform which is being developed for peripheral neuropathic ache.

This follows the current approvals from regulatory authorities to begInside the research. The Half II medical trial is a double-blind, placebo-managed, randomized cross-over research evaluating the efficacy, safety, and pharmacokinetics of AlzeCure’s main drug candidate in ache, ACD440. Outcomes from the research are anticipated in mid-2023.

ACD440 is a TRPV1 antagonist and first-in-class native remedy for affected individuals with peripheral neuropathic ache. The invention of TRPV1, which is The idea for the enterprise, was awarded the Nobel Prize in Physiology or Medicine in 2021. ACD440, which is utilized as a gel, is The agency’s main drug candidate Inside the Painless platform and carried out a constructive phase Ib research in 2021.

The medical want in neuropathic ache Might be very good, not least To Search out options to opioids. The market for neuropathic ache is The solely largest market phase in ache remedy, with annual gross sales of over USD 11 billion. As a lot as 80% …….

Source: https://www.biospace.com/article/releases/first-patient-included-in-alzecure-s-phase-ii-clinical-trial-in-neuropathic-pain-with-non-opioid-acd440/

Related Posts

npressfetimg-29461.png

New ‘digital masks’ touted as means of protecting patient privacy – Healthcare Finance News

Photo: Al David Sacks/Getty Images

Technologists writing in the journal Nature have created a digital “mask,” dubbed the DM, which they say offers a pragmatic approach to safeguarding patient privacy in electronic health records and during virtual healthcare visits.

There appear to be clinical benefits to the DM as well.

The technology is based on real-time 3D reconstructio…….

npressfetimg-28933.png

State Rules Stymie Patient Access to Care at Opioid Treatment Centers – PatientEngagementHIT.com

Checking if the site connection is secure

Enable JavaScript and cookies to continue

…….

npressfetimg-28758.png

Top Ranked for Quality & Patient Safety – NYU Langone Health

NYU Langone Health has the highest quality of care and patient safety rankings of any healthcare organization in the country. Each day, we ensure that we are delivering the best in all aspects of care across our hospitals and health system. Our exceptional quality and safety standards have made us the top-rated healthcare system in the New York City area and placed us among the top-ranked …….

npressfetimg-28699.png

COVID-19 rehabilitation patient leaflet hugely popular – World Health Organization

Recognizing early that rehabilitation would be essential for many in their recovery from COVID-19 infection, WHO/Europe quickly convened experts and people recovering from COVID-19 to produce the patient leaflet ‘Support for rehabilitation: self-management after COVID-19-related illness’. 

The resource provides evidence-based support and advice for adults who are recovering from COVI…….

npressfetimg-27757.png

Uninsured, Publicly Insured Patients Face Implicit Bias in Health – PatientEngagementHIT.com

Checking if the site connection is secure

Enable JavaScript and cookies to continue

…….

npressfetimg-27698.png

AI Brings New Opportunities for Patient Financial Navigation – Managed Healthcare Executive

The confusing, data-intensive world of getting help with medical bills has become a fertile territory for software developers.

When patients need help paying for high-cost medical treatment, they face a good news/bad news scenario.

The good news is that drugmakers, private foundations, government agencies and others have myriad programs that can help many if not all. The bad: Actual…….

Leave a Reply

Your email address will not be published. Required fields are marked *